SCHEMBL12781007

SCHEMBL12781007

CN(C)/C=N/S(=O)(=O)c1cccc(Nc2nc(N)n(-c3nc4ccccc4s3)n2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 3/20 0.46
▸ AXL P30530 1/20 0.43
▸ RAB9A P51151 4/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ MAPK1 P28482 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ MAPT P10636 3/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ FLT3 P36888 2/20 0.37
▸ KIT P10721 1/20 0.37
▸ JAK1 P23458 2/20 0.36
▸ JAK3 P52333 2/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ TYK2 P29597 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.35
▸ HTT P42858 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ NFKB2 Q00653 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12780945 0.84 JAK3 (0.51) BACE1AXLRAB9ANPC1MAPK1
SCHEMBL12781069 0.83 BACE1 (0.49) BACE1AXLRAB9ANPC1MAPK1
SCHEMBL12781080 0.81 SRC (0.49) BACE1AXLRAB9ANPC1MAPK1
SCHEMBL12781077 0.80 BACE1 (0.53) BACE1AXLRAB9AMAPK1KMT2A
SCHEMBL12780981 0.79 BACE1 (0.52) BACE1AXLRAB9ANPC1MAPK1
SCHEMBL12781039 0.78 BACE1 (0.46) BACE1AXLRAB9ANPC1MAPK1
SCHEMBL12780930 0.78 BACE1 (0.54) BACE1AXLRAB9ANPC1MAPK1
SCHEMBL12781000 0.77 BACE1 (0.56) BACE1AXLRAB9ANPC1MAPK1
SCHEMBL12781051 0.77 BACE1 (0.54) BACE1AXLRAB9ANPC1MAPK1
SCHEMBL12781049 0.77 LMNA (0.55) BACE1RAB9ANPC1MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 — — US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 — — US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 — — US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 — — US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 BACE1 3044/4885AXL 762/4885RAB9A 3309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback